DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Luke Miels - 2 Pascal Soriot - 1 AstraZeneca’s - 1 Ivan Menezes - 1 Debra Crew - 1 Soriot - 1 Susan Galbraith - 1 David Fredrickson - 1
Top related locs:
AstraZeneca’s Swedish British Europe U.S London Bengaluru
Top related orgs:
Pfizer - 2 GSK - 2 Thomson - 2 pharma - 1 Novartis - 1 Sanofi - 1 AstraZeneca - 1 Diageo - 1

Search resuls for: "Luke Miels"


3 mentions found


☆ AstraZeneca succession sickness demands urgent fix
  + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +3 min
LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.
Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish
☆ EU approves its first vaccine for common respiratory virus RSV
  + stars: | 2023-06-07 | by ( Natalie Grover Eva Mathews | Natalie Grover | Eva Mathews | ) www.reuters.com   time to read: +2 min
June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually. The shot, called Arexvy, is made by British drugmaker GSK (GSK.L) and is designed to protect people aged 60 and over. The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956. Given the different definitions of the trial endpoints across the GSK and Pfizer trials, a direct comparison of efficacy is difficult. In Europe, RSV leads to over 270,000 hospitalisations and about 20,000 in-hospital deaths in adults over 60 each year.
Persons: Luke Miels, Peter Welford, TD Cowen, Steve Scala, Natalie Grover, Eva Mathews, Maggie Fick, Savio D'Souza, Mark Potter Organizations: GSK, European Commission, European Medicines Agency, Reuters, U.S . Food, Drug Administration, Pfizer, Jefferies, Thomson Locations: British, Europe, U.S, London, Bengaluru
☆ US FDA approves first RSV vaccine from GSK
  + stars: | 2023-05-03 | by ( ) www.reuters.com   time to read: +1 min
May 3 (Reuters) - The U.S. Food and Drug Administration has approved GSK Plc's (GSK.L) respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The vaccine was approved for people aged 60 and older, the company said. The approval makes GSK, which has been neck-and-neck with Pfizer (PFE.N) in RSV vaccine development, the first company to tap into a multi-billion-dollar market and puts it ahead of rivals such as Moderna Inc (MRNA.O) and Bavarian Nordic (BAVA.CO). Analysts have estimated the market for RSV vaccines to cross $10 billion by 2030. GSK expects the vaccine to be available before the next RSV season in the United States, Chief Commercial Officer Luke Miels told Reuters on Wednesday before the approval.
0 next >>
Total: 3